TABLE 1.
Patient populations
| Characteristic | No. of patients
|
|||
|---|---|---|---|---|
| Anidulafungin dose group (mg)
|
Total | |||
| 50 | 75 | 100 | ||
| Randomized | 42 | 40 | 41 | 123 |
| Never received study drug | 2 | 0 | 1 | 3 |
| ITT | 40 | 40 | 40 | 120 |
| No baseline pathogen | 3 | 0 | 1 | 4 |
| MITT | 37 | 40 | 39 | 116 |
| <10 days of anidulafungina | 9 | 8 | 8 | 25 |
| Concomitant antifungal therapy before EOT | 3 | 1 | 1 | 5 |
| Indeterminate clinical-microbiological response | 0 | 1 | 2 | 3 |
| Evaluable at EOT | 25 | 30 | 28 | 83 |
| Concomitant antifungal therapy before FU | 1 | 3 | 1 | 5 |
| Indeterminate clinical-microbiological response | 6 | 1 | 3 | 10 |
| Evaluable at FU | 18 | 26 | 24 | 68 |
a
Patients who received at least 5 days of anidulafungin and had a clinical response of failure at EOT were not excluded from the evaluable populations.